This indicates that the anti-TCP1 antibody is more prevalent in the serum of SLE patients compared to the three anti-RPLP antibodies, suggesting that anti-TCP1 could serve as a potential biomarker for SLE. Here, TCP1 is linked to systemic lupus erythematosus.